European Healthcare Acquisition & Growth Company B.V. (EHCS.AS) operates as a blank-check special purpose acquisition company focused on effecting mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations with one or more operating businesses primarily in the European healthcare sector; it targets subsectors including biotechnology and specialty pharma, pharma services, medical technology and medical devices, diagnostic and lab services, bioinformatics, and life science tools. Incorporated in 2021 and headquartered at Theresienhöhe 28, 80339 Munich, Germany, the company serves as the first operators-led, healthcare-focused acquisition vehicle in Europe, leveraging management expertise to identify and integrate targets across these therapeutic and technology-driven areas. Geographically, it concentrates on companies with principal operations in Europe, providing a structured framework for investors seeking exposure to high-growth healthcare opportunities through sponsored SPAC investments. In recent developments, the company announced its dissolution in November 2024, with delisting from Euronext Amsterdam following the expiry of its acquisition mandate without completing a business combination; it also reported a CEO change in May 2024, published its half-year results in September 2024, and held its final annual general meeting in June 2024 ahead of liquidation proceedings.